2. Search Result
Search Result
Results for "

Cachexia

" in MedChemExpress (MCE) Product Catalog:

37

Inhibitors & Agonists

5

Peptides

1

Inhibitory Antibodies

4

Natural
Products

4

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-156354
    GPR61 Inverse agonist 1

    		Orphan Receptor Metabolic Disease
    GPR61 Inverse agonist 1 (Compound 1) is a GPR61 inverse agonist (IC50: 11 nM). GPR61 Inverse agonist 1 can be used for research of disorders of metabolism and body weight, such as obesity and cachexia .
    GPR61 Inverse agonist 1
  • HY-13676
    Megestrol acetate
    2 Publications Verification

    		 Progesterone Receptor Autophagy HIV Endocrinology Cancer
    Megestrol acetate is a synthetic and orally active progesteronal agent. Megestrol acetate is effective as an appetite stimulant for wasting syndromes such as cachexia. Megestrol acetate decreases nuclear and cytosol androgen receptors human BPH tissue. Megestrol acetate has the potential for HIV study and downregulates autophagic catabolic pathway .
    Megestrol acetate
  • HY-12176
    Aliskiren
    5+ Cited Publications

    CGP 60536; CGP60536B; SPP 100

    		 Renin Autophagy Cardiovascular Disease Cancer
    Aliskiren is an orally active, highly potent and selective renin inhibitor, with IC50 of 1.5 nM. Aliskiren can be used for the research of hypertension, cardiovascular diseases and cancer cachexia .
    Aliskiren
  • HY-P5971
    TCMCB07

    Mifomelatide

    		 Melanocortin Receptor Metabolic Disease
    TCMCB07, a cyclic nonapeptide peptide, is an orally active and brain-penetrant melanocortin receptor 4 (MC4R) antagonist. TCMCB07 plays an important role in cachexia .
    TCMCB07
  • HY-129531
    MuRF1-IN-1

    		E1/E2/E3 Enzyme Neurological Disease
    MuRF1-IN-1 is an orally active MuRF1 inhibitor. MuRF1-IN-1 can inhibit the interaction between MuRF1 and titin as well as E3 ligase activity. MuRF1-IN-1 can alleviate skeletal muscle atrophy and dysfunction in cardiac cachexia .
    MuRF1-IN-1
  • HY-P5971A
    TCMCB07 TFA

    		Melanocortin Receptor Metabolic Disease
    TCMCB07 TFA, a cyclic nonapeptide peptide, is an orally active and brain-penetrant melanocortin receptor 4 (MC4R) antagonist. TCMCB07 TFA plays an important role in cachexia .
    TCMCB07 TFA
  • HY-12177
    Aliskiren hemifumarate
    5+ Cited Publications

    CGP 60536 hemifumarate; CGP60536B hemifumarate; SPP 100 hemifumarate

    		 Renin Autophagy Cardiovascular Disease Cancer
    Aliskiren (CGP 60536; CGP60536B; SPP 100) hemifumarate is an orally active and selective renin inhibitor, with IC50 of 1.5 nM. Aliskiren hemifumarate can be used for the research of hypertension, cardiovascular diseases and cancer cachexia .
    Aliskiren hemifumarate
  • HY-12176B
    Aliskiren fumarate

    CGP 60536 fumarate; CGP60536B fumarate; SPP 100 fumarate

    		 Renin Autophagy Cardiovascular Disease Cancer
    Aliskiren fumarate is an orally active, highly potent and selective renin inhibitor, with IC50 of 1.5 nM. Aliskiren fumarate can be used for the research of hypertension, cardiovascular diseases and cancer cachexia .
    Aliskiren fumarate
  • HY-12176A
    Aliskiren hydrochloride

    CGP 60536 hydrochloride; CGP60536B hydrochloride; SPP 100 hydrochloride

    		 Renin Autophagy Cardiovascular Disease Cancer
    Aliskiren (CGP 60536; CGP60536B; SPP 100) hydrochloride is an orally active and selective renin inhibitor, with IC50 of 1.5 nM. Aliskiren hydrochloride can be used for the research of hypertension, cardiovascular diseases and cancer cachexia - .
    Aliskiren hydrochloride
  • HY-12176R
    Aliskiren (Standard)

    CGP 60536 (Standard); CGP60536B (Standard); SPP 100 (Standard)

    		 Reference Standards Renin Autophagy Cardiovascular Disease Cancer
    Aliskiren (Standard) is the analytical standard of Aliskiren. This product is intended for research and analytical applications. Aliskiren is an orally active, highly potent and selective renin inhibitor, with IC50 of 1.5 nM. Aliskiren can be used for the research of hypertension, cardiovascular diseases and cancer cachexia .
    Aliskiren (Standard)
  • HY-148349
    PF-07258669

    		Melanocortin Receptor Neurological Disease Metabolic Disease
    PF-07258669 is an orally active melanocortin-4 receptor (MC4R) antagonist that antagonizes MC4R with an IC50 of 13 nM (Ki=0.46 nM). PF-07258669 can be used for the research of cachexia, anorexia, or anorexia nervosa .
    PF-07258669
  • HY-12177R
    Aliskiren hemifumarate (Standard)

    		Renin Autophagy Cardiovascular Disease Cancer
    Aliskiren (hemifumarate) (Standard) is the analytical standard of Aliskiren (hemifumarate). This product is intended for research and analytical applications. Aliskiren (CGP 60536; CGP60536B; SPP 100) hemifumarate is an orally active and selective renin inhibitor, with IC50 of 1.5 nM. Aliskiren hemifumarate can be used for the research of hypertension, cardiovascular diseases and cancer cachexia .
    Aliskiren hemifumarate (Standard)
  • HY-161875
    NAT1-IN-1

    		Histone Acetyltransferase Metabolic Disease Cancer
    NAT1-IN-1 (compound 350) is a potent N-acetyltransferase 1 (NAT1)-targeted inhibitor, with an IC50 of 44 nM. NAT1-IN-1 can be used for the research of hypermetabolic diseases such as amyotrophic lateral sclerosis, cancer cachexia, and sepsis .
    NAT1-IN-1
  • HY-100186
    GSK-2881078
    4 Publications Verification

    		 Androgen Receptor Cardiovascular Disease Others Metabolic Disease Inflammation/Immunology Endocrinology Cancer
    GSK-2881078 is an orally active and nonsteroidal selective androgen receptor modulator (SARM) which act as partial AR agonists in androgenic tissues while mainly as complete AR agonists in synthetic metabolic tissues,induces AR-mediated transcriptional activation in PC3(AR)2 cells (EC50 = 3.99 nM) and the effect can be inhibited by the non-steroidal AR antagonist Bicalutamide. GSK-2881078 can be used in research of muscle weakness and cachexia associated with both chronic and acute illness .
    GSK-2881078
  • HY-19884
    Relamorelin

    RM-131; BIM-28131

    		 GHSR Metabolic Disease
    Relamorelin (RM-131), a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin is centrally penetrant. Relamorelin increases growth hormone levels and accelerates gastric emptying. Relamorelin has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research .
    Relamorelin
  • HY-19884A
    Relamorelin acetate

    RM-131 acetate; BIM-28131 acetate

    		 GHSR Metabolic Disease
    Relamorelin (RM-131) acetate, a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin acetate is centrally penetrant. Relamorelin acetate increases growth hormone levels and accelerates gastric emptying. Relamorelin acetate has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research .
    Relamorelin acetate
  • HY-19884B
    Relamorelin TFA

    RM-131 TFA; BIM-28131 TFA

    		 GHSR Metabolic Disease
    Relamorelin (RM-131) TFA, a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin TFA is centrally penetrant. Relamorelin TFA increases growth hormone levels and accelerates gastric emptying. Relamorelin TFA has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research .
    Relamorelin TFA
  • HY-N0109
    Salidroside
    Maximum Cited Publications
    34 Publications Verification

    Rhodioloside

    		 PINK1/Parkin mTOR Apoptosis Prolyl Endopeptidase (PREP) Cancer
    Salidroside (Rhodioloside) is a prolyl endopeptidase inhibitor. Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mTOR signalling. Salidroside protects dopaminergic neurons by enhancing PINK1/Parkin-mediated mitophagy.
    Salidroside
  • HY-N0109R
    Salidroside (Standard)
    Maximum Cited Publications
    34 Publications Verification

    Rhodioloside (Standard)

    		 Prolyl Endopeptidase (PREP) mTOR Apoptosis PINK1/Parkin Reference Standards Cancer
    Salidroside (Standard) is the analytical standard of Salidroside. This product is intended for research and analytical applications. Salidroside (Rhodioloside) is a prolyl endopeptidase inhibitor. Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mTOR signalling. Salidroside protects dopaminergic neurons by enhancing PINK1/Parkin-mediated mitophagy.
    Salidroside (Standard)
  • HY-B1834
    Megestrol

    		Drug Metabolite Inflammation/Immunology Cancer
    Megestrol is a synthetic progestin and used for the treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with an acquired immunodeficiency syndrome diagnosis .
    Megestrol
  • HY-18102
    GLPG0492
    5+ Cited Publications

    		 Androgen Receptor Others
    GLPG0492 is a non-steroidal selective androgen receptor modulator (potency 12 nM). GLPG0492 has the potential for the research of musculo-skeletal diseases such as sarcopenia and cachexia .
    GLPG0492
  • HY-B1834S1
    Megestrol-d5

    		Isotope-Labeled Compounds Drug Metabolite Inflammation/Immunology
    Megestrol-d5 is the deuterium labeled Megestrol. Megestrol is a synthetic progestin and used for the treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with an acquired immunodeficiency syndrome diagnosis .
    Megestrol-d5
  • HY-B1834R
    Megestrol (Standard)

    		Reference Standards Drug Metabolite Inflammation/Immunology Cancer
    Megestrol (Standard) is the analytical standard of Megestrol. This product is intended for research and analytical applications. Megestrol is a synthetic progestin and used for the treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with an acquired immunodeficiency syndrome diagnosis .
    Megestrol (Standard)
  • HY-W747043
    Megestrol-d3

    		Isotope-Labeled Compounds Drug Metabolite Inflammation/Immunology
    Megestrol-d3 is the deuterium labeled Megestrol (HY-B1834). Megestrol is a synthetic progestin and used for the treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with an acquired immunodeficiency syndrome diagnosis .
    Megestrol-d3
  • HY-14820A
    Macimorelin acetate

    EP-1572 acetate; AEZS-130 acetate

    		 GHSR Neurological Disease Endocrinology Cancer
    Macimorelin (EP-1572) acetate, a GH secretagogue, is an orally active GHSR agonist. Macimorelin acetate stimulates GH release. Macimorelin acetate can be used in the research of adult growth hormone deficiency (AGHD), and Cancer anorexia-cachexia syndrome (CACS) .
    Macimorelin acetate
  • HY-14820
    Macimorelin

    EP-1572; AEZS-130

    		 GHSR Endocrinology Cancer
    Macimorelin (EP-1572), a GH secretagogue, is an orally active GHSR agonist. Macimorelin stimulates GH release. Macimorelin can be used in the research of adult growth hormone deficiency (AGHD), and Cancer anorexia-cachexia syndrome (CACS) .
    Macimorelin
  • HY-B0580B
    (R)-Ketorolac
    1 Publications Verification

    (+)-Ketorolac

    		 Ras Cancer
    (R)-Ketorolac is an orally active Cdc42 and Rac1 inhibitor. (R)-Ketorolac inhibits GTPase. (R)-Ketorolac alters ovarian cancer cell behaviors critical for invasion and metastasis. (R)-Ketorolac ameliorates cancer-associated cachexia .
    (R)-Ketorolac
  • HY-14734
    Anamorelin
    5+ Cited Publications

    RC-1291; ONO-7643

    		 GHSR Endocrinology Cancer
    Anamorelin (RC-1291) is an orally active Ghrelin receptor agonist with an EC50 of 0.74 nM. Anamorelin can promote appetite, increase body weight, and stimulate the secretion of growth hormone and insulin-like growth factor-1. Anamorelin can be used in the research of anorexia and cancer cachexia .
    Anamorelin
  • HY-14734B
    Anamorelin Fumarate

    RC-1291 Fumarate; ONO-7643 Fumarate

    		 GHSR Endocrinology Cancer
    Anamorelin (RC-1291) Fumarate is an orally active Ghrelin receptor agonist with an EC50 of 0.74 nM. Anamorelin Fumarate can promote appetite, increase body weight, and stimulate the secretion of growth hormone and insulin-like growth factor-1. Anamorelin Fumarate can be used in the research of anorexia and cancer cachexia .
    Anamorelin Fumarate
  • HY-14734A
    Anamorelin hydrochloride
    5+ Cited Publications

    RC-1291 hydrochloride; ONO-7643 hydrochloride

    		 GHSR Endocrinology Cancer
    Anamorelin (RC-1291) hydrochloride is an orally active Ghrelin receptor agonist with an EC50 of 0.74 nM. Anamorelin hydrochloride can promote appetite, increase body weight, and stimulate the secretion of growth hormone and insulin-like growth factor-1. Anamorelin hydrochloride can be used in the research of anorexia and cancer cachexia .
    Anamorelin hydrochloride
  • HY-P99241
    Ponsegromab
    1 Publications Verification

    PF 06946860

    		 TGF-beta/Smad Cancer
    Ponsegromab (PF 06946860) is a potent and selective humanized anti-GDF15 monoclonal antibody with anti-cachexia activity. Ponsegromab binds to GDF15 and prevents the binding of GDF15 to GFRAL, thereby blocking GDF15/GFRAL-mediated signaling. Ponsegromab can be used in the research of cancers .
    Ponsegromab
  • HY-13676S
    Megestrol acetate-d3

    		Isotope-Labeled Compounds Progesterone Receptor Autophagy HIV Endocrinology Cancer
    Megestrol acetate-d3 is the deuterium labeled Megestrol acetate. Megestrol acetate is a synthetic and orally active progesteronal agent. Megestrol acetate is effective as an appetite stimulant for wasting syndromes such as cachexia. Megestrol acetate decreases nuclear and cytosol androgen receptors human BPH tissue. Megestrol acetate has the potential for HIV study and downregulates autophagic catabolic pathway .
    Megestrol acetate-d3
  • HY-13676S1
    Megestrol acetate-d3-1

    		Isotope-Labeled Compounds Progesterone Receptor Autophagy HIV Endocrinology Cancer
    Megestrol acetate-d3-1 is deuterium labeled Megestrol acetate. Megestrol acetate is a synthetic and orally active progesteronal agent. Megestrol acetate is effective as an appetite stimulant for wasting syndromes such as cachexia. Megestrol acetate decreases nuclear and cytosol androgen receptors human BPH tissue. Megestrol acetate has the potential for HIV study and downregulates autophagic catabolic pathway .
    Megestrol acetate-d3-1
  • HY-13676R
    Megestrol acetate (Standard)
    2 Publications Verification

    		 Reference Standards Progesterone Receptor Autophagy HIV Endocrinology Cancer
    Megestrol acetate (Standard) is the analytical standard of Megestrol acetate. This product is intended for research and analytical applications. Megestrol acetate is a synthetic and orally active progesteronal agent. Megestrol acetate is effective as an appetite stimulant for wasting syndromes such as cachexia. Megestrol acetate decreases nuclear and cytosol androgen receptors human BPH tissue. Megestrol acetate has the potential for HIV study and downregulates autophagic catabolic pathway .
    Megestrol acetate (Standard)
  • HY-14734R
    Anamorelin (Standard)

    RC-1291 (Standard); ONO-7643 (Standard)

    		 Reference Standards GHSR Endocrinology Cancer
    Anamorelin (Standard) (RC-1291 (Standard)) is the analytical standard of Anamorelin (HY-14734). This product is intended for research and analytical applications. Anamorelin (RC-1291) is an orally active Ghrelin receptor agonist with an EC50 of 0.74 nM. Anamorelin can promote appetite, increase body weight, and stimulate the secretion of growth hormone and insulin-like growth factor-1. Anamorelin can be used in the research of anorexia and cancer cachexia .
    Anamorelin (Standard)
  • HY-129692
    Withanone
    1 Publications Verification

    		 iGluR Neurological Disease Cancer
    Withanone is an active ingredient from the roots of Withania somnifera and a GRP75 inhibitor. Withanone has multifunctional neuroprotective effects in alleviating cognitive dysfunction. In neuron-like cells, Withanone can inhibit NMDA-induced excitotoxicity. Withanone can inhibit white adipose tissue browning by blocking the formation of the GRP75-ANT2-UCP1 complex, thereby alleviating cancer-related cachexia. Withanone can be used in the research of tumors and nervous system diseases .
    Withanone
  • HY-129692R
    Withanone (Standard)

    		Reference Standards iGluR Neurological Disease Cancer
    Withanone (Standard) is the analytical standard of Withanone (HY-129692). This product is intended for research and analytical applications. Withanone is an active ingredient from the roots of Withania somnifera and a GRP75 inhibitor. Withanone has multifunctional neuroprotective effects in alleviating cognitive dysfunction. In neuron-like cells, Withanone can inhibit NMDA-induced excitotoxicity. Withanone can inhibit white adipose tissue browning by blocking the formation of the GRP75-ANT2-UCP1 complex, thereby alleviating cancer-related cachexia. Withanone can be used in the research of tumors and nervous system diseases .
    Withanone (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: